Shots:

• The P-III (CERTAIN-1) study evaluates cefepime-taniborbactam vs meropenem in a ratio (2:1) in 661 patients with cUTI including acute pyelonephritis
• The trial met its 1EPs of non-inferiority (NI) in microITT population at TOC ( 70.0% vs 58.0%). A prespecified test showed the superiority of cefepime-taniborbactam for the composite EPs at TOC & was sustained in the composite microbiologic & clinical response at late-follow-pp (Day 28-35) visit
• Serious TEAEs (2.0% vs 1.8%), treatment discontinuations due to TEAEs (3.0% vs 0.9%). Under an exclusive licensing agreement with Venatorx, Everest gets the rights to develop & commercialize the product in Mainland China & 10 other countries

Ref: PR Newswire | Image: Everest Medicines